Biomedical company Oxford expands cancer gene therapy technology business: and gets investment
Biotech company Oxford Genetics invests $1.2 million to expand cancer gene therapy technology business
Recently, DNA design biotechnology company Oxford Genetics announced a $1.2 million financing, invested by Mercia Technologies, an investment company focused on technology. The financing will be used to expand the operations of Oxford Genetics and assist the company in expanding its services to provide cancer gene therapy technology.
Oxford Genetics was founded in 2011 and is headquartered in Oxford, England. The team is composed of genetic engineering experts from all fields of biology and specializes in providing a variety of DNA expression vectors for scientific users and biotechnology industry users in different fields of biology to meet the needs of various biological research. The company also provides scientists with a universal cloning platform and a DNA insertion matching library with various biomolecular components for mammalian, bacterial and phage systems, which can solve the cloning problems prevalent in current genetic engineering research.
In addition to this financing, Oxford Genetics recently announced that it has moved to the Oxford Science Park with state-of-the-art facilities, and its team will be able to use its specialized cell development kits and corresponding automation technologies to significantly increase its capacity to meet its growing Customer needs.
drainage catheter, pigtail biliary nephrostomy drainage catheter, pigtail drainage catheter
Anesthesia Medical Co., Ltd. , https://www.jssinoanesthesias.com